Skip to main content
HitGen Inc. logo

HitGen Inc. — Investor Relations & Filings

Ticker · 688222 ISIN · CNE1000040G3 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 629 across all filing types
Latest filing 2023-05-19 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688222

About HitGen Inc.

https://www.hitgen.com/en

HitGen Inc. is a technology-driven research and development organization focused on the discovery of novel small molecule drug candidates. The company leverages its proprietary DNA-encoded library (DEL) platform, which features a collection of over 1.2 trillion diverse small molecules, to enable efficient hit identification and lead optimization. HitGen offers integrated drug discovery services, incorporating fragment-based drug discovery (FBDD) and structure-based drug design through its specialized research facilities. Its core operations include collaborative research partnerships with global pharmaceutical entities and the development of an internal pipeline of therapeutic programs. The platform combines synthetic chemistry, biology, and data informatics to streamline the identification of bioactive compounds for complex therapeutic targets.

Recent filings

Filing Released Lang Actions
中国国际金融股份有限公司关于成都先导药物开发股份有限公司2022年度持续督导跟踪报告
Regulatory Filings
2023-05-19 Chinese
成都先导药物开发股份有限公司关于召开2022年度暨2023年第一季度业绩说明会的公告
Regulatory Filings Classification · 95% confidence The document is an announcement about the scheduling of an investor earnings explanation meeting (业绩说明会) for the 2022 annual and 2023 first quarter results. It provides details on the meeting time, location, participation method, and contact information. It references that the 2022 annual report and 2023 Q1 report have already been disclosed on the exchange website. The document itself does not contain financial data or the actual report but is an announcement of the upcoming earnings call/meeting. Given the content and length (1566 characters), it is not the earnings release itself but an announcement of the earnings explanation meeting. This fits best with the category of Call Transcript (CT) or Investor Presentation (IP). However, since it is an announcement of the earnings explanation meeting (not the transcript or presentation itself), and the document is short and only announces the event, it aligns best with Regulatory Filings (RNS) as a general announcement. But since the category CT is defined as the full transcript, and IP as detailed presentation, and this is only an announcement, the best fit is Regulatory Filings (RNS). However, the instructions say that announcements of meetings are not specifically listed, and RNS is the fallback for miscellaneous filings. Therefore, the classification is RNS with high confidence.
2023-05-11 Chinese
成都先导药物开发股份有限公司2022年年度股东大会会议资料
AGM Information Classification · 100% confidence The document is titled as "2022 年年度股东大会会议资料" which translates to "2022 Annual General Meeting (AGM) Meeting Materials". It contains detailed agenda, reports, and proposals to be discussed and voted on during the 2022 AGM of the company 成都先导药物开发股份有限公司. The content includes meeting notices, voting procedures, board and supervisory reports, and other materials typically shared at an AGM. The document length is substantial (15,000 characters), indicating it is the actual meeting materials, not just an announcement or summary. Therefore, this document fits the category of AGM Information (AGM-R).
2023-05-10 Chinese
德勤华永会计师事务所（特殊普通合伙）关于成都先导药物开发股份有限公司2022年财务报表及审计报告
Regulatory Filings
2023-04-28 Chinese
成都先导药物开发股份有限公司关于使用剩余超募资金永久补充流动资金的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement by Chengdu Lead Drug Development Co., Ltd. regarding the use of remaining over-raised funds to permanently supplement working capital. It details the background of the fundraising, the amount of funds raised, the usage of the funds, and the approval process including board and supervisory committee opinions. The document references regulatory guidelines and approvals but does not contain financial statements or detailed financial performance data. It is a specific update on capital usage related to fundraising proceeds, which fits the category of Capital/Financing Update (CAP). The document length is about 4,083 characters, which is sufficient for a detailed announcement but not a full financial report. Therefore, the classification is CAP with high confidence.
2023-04-28 Chinese
成都先导药物开发股份有限公司2022年度利润分配预案公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the 2022 annual profit distribution plan of Chengdu Lead Drug Development Co., Ltd. It details the company's decision not to distribute additional cash dividends or shares, explains the reasons including share repurchase details, and mentions that the plan will be submitted to the shareholders' meeting for approval. The document is relatively short (2117 characters) and serves as a formal announcement of the profit distribution plan rather than the full annual report or financial statements. It does not contain comprehensive financial data or detailed financial performance analysis. Therefore, it fits best into the category of Notice of Dividend Amount (DIV), as it announces the dividend distribution plan and related shareholder information.
2023-04-28 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.